Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7064148 | SUCAMPO PHARMA LLC | Chloride channel opener |
Aug, 2022
(1 year, 6 months ago) | |
US8097653 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(1 year, 4 months ago) | |
US8389542 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(1 year, 4 months ago) | |
US6982283 | SUCAMPO PHARMA LLC | Method for treating drug-induced constipation |
Dec, 2022
(1 year, 3 months ago) | |
US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(5 months from now) | |
US8748481 | SUCAMPO PHARMA LLC | Method for treating gastrointestinal disorder |
Sep, 2025
(1 year, 5 months from now) | |
US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(2 years from now) | |
US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(2 years from now) | |
US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(3 years from now) |
Amitiza is owned by Sucampo Pharma Llc.
Amitiza contains Lubiprostone.
Amitiza has a total of 9 drug patents out of which 4 drug patents have expired.
Expired drug patents of Amitiza are:
Amitiza was authorised for market use on 31 January, 2006.
Amitiza is available in capsule;oral dosage forms.
Amitiza can be used as method for treating opioid-induced constipation, use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient, method for treating constipation in a patient with opioid-induced constipation by opening cic channels; method of treating constipation in a patient with irritable bowel syndrome by opening chloride channels (cic); method for treating constipation by opening cic channels in a mammalian subject, method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome, method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome; method for the long term treatment of chronic constipation in a human subject, method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
The generics of Amitiza are possible to be released after 25 October, 2027.
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 31 January, 2006
Treatment: Method for treating constipation in a patient with opioid-induced constipation by opening cic channels; Method of treating constipation in a patient with irritable bowel syndrome by opening chloride c...
Dosage: CAPSULE;ORAL